CONDITION

Lymphoma in Dogs

A cancer of the lymphatic system that can present in multiple forms and locations, affecting organ function and wellbeing.

Why this matters now

Lymphoma is one of the most commonly diagnosed cancers in dogs, accounting for a significant proportion of all canine malignancies. It can develop at any age but is most frequently diagnosed in middle-aged to older dogs, typically between six and twelve years of age. Certain breeds appear to carry an increased predisposition, including Golden Retrievers, Labrador Retrievers, Boxers, Bernese Mountain Dogs, Rottweilers, and Scottish Terriers, though no breed is immune. The condition can arise without any identifiable prior illness or exposure, and while environmental factors such as herbicide exposure and immune system dysfunction have been investigated as potential risk factors, the causative mechanisms remain incompletely understood. The multicentric form, involving enlargement of peripheral lymph nodes throughout the body, is the most common presentation, though lymphoma can originate in virtually any organ system.

The behaviour and progression of lymphoma in dogs is influenced substantially by the anatomical form, the immunophenotype (B-cell versus T-cell), the histological grade, and the individual animal's immune response. Multicentric lymphoma often progresses relatively rapidly if untreated, with generalised lymph node enlargement sometimes developing over just a few weeks. Some dogs remain remarkably well despite extensive lymph node involvement, whilst others develop systemic illness — including lethargy, weight loss, inappetence, and organ dysfunction — as the disease advances. The rate of progression varies between individuals, and some forms of lymphoma, particularly certain T-cell subtypes and high-grade variants, tend to follow a more aggressive course than others. Without intervention, the natural course of most forms of canine lymphoma tends towards progressive deterioration over a period of weeks to a few months, though individual variation exists.

Signals & patterns

Early signals

Painless lymph node enlargement

The most common initial observation in multicentric lymphoma is the appearance of firm, painless swellings beneath the skin, particularly in the areas under the jaw (submandibular), in front of the shoulders (prescapular), behind the knees (popliteal), and in the groin (inguinal). These enlarged lymph nodes may be discovered incidentally during grooming, petting, or routine veterinary examination. The swellings are typically smooth, mobile, and symmetrically distributed, and may enlarge rapidly over days to weeks.

Subtle energy changes

Some dogs may show mild reductions in energy or enthusiasm for activities before more obvious signs develop. They may rest more frequently, seem slightly less engaged in play, or show reduced interest in walks. These changes can be easily overlooked or attributed to other factors, particularly in older dogs where some slowing may be expected.

Mild appetite fluctuation

Early changes in eating behaviour may include slight reductions in appetite, increased selectivity about food, or eating more slowly than usual. Some dogs maintain normal appetite throughout the early stages, making this an inconsistent early indicator. When present, these changes may reflect the systemic effects of the developing cancer or mild gastrointestinal involvement.

Increased thirst and urination

In cases where lymphoma causes paraneoplastic hypercalcaemia (elevated blood calcium levels, particularly associated with T-cell lymphoma), increased water intake and more frequent urination may be among the earliest observable changes. The elevated calcium affects kidney function, reducing the kidneys' ability to concentrate urine. This sign may precede recognisable lymph node enlargement in some cases.

Intermittent digestive changes

Occasional vomiting, soft stools, or mild diarrhoea may occur, particularly if there is early gastrointestinal involvement or if systemic effects of the disease begin to affect normal digestive function. These signs are typically intermittent and non-specific in the early stages. Alimentary (gastrointestinal) lymphoma may present with digestive signs as the primary initial observation rather than palpable lymph node enlargement.

Later signals

Progressive weight loss and muscle wasting

As the disease advances, noticeable weight loss and loss of muscle mass may develop despite apparently adequate food intake. This cancer-related wasting, sometimes termed cancer cachexia, results from altered metabolism driven by the tumour's metabolic demands and the body's inflammatory response to the cancer. The weight loss may be most visible over the spine, hindquarters, and temples.

Organ-specific signs

Depending on which organs become infiltrated, various specific signs may emerge. Hepatic (liver) involvement may produce jaundice, abdominal distension from fluid accumulation, or digestive disturbance. Splenic involvement may cause abdominal enlargement. Mediastinal lymphoma can cause breathing difficulty due to fluid accumulation around the lungs or compression of airways. Cutaneous lymphoma may manifest as skin lesions, nodules, or plaques. The pattern of organ involvement influences the specific clinical picture considerably.

Marked lethargy and withdrawal

Progressive fatigue, decreased interest in surroundings, reluctance to engage in previously enjoyed activities, and increased time spent sleeping may become prominent as the disease advances. The dog may seek isolation, show reduced responsiveness to familiar stimuli, or appear generally unwell. These behavioural changes often reflect the cumulative systemic burden of advancing disease.

Breathing changes

Respiratory involvement — whether through direct infiltration of lung tissue, accumulation of fluid in the chest cavity (pleural effusion), or enlargement of mediastinal lymph nodes — can produce increased respiratory rate, laboured breathing, or episodes of breathing difficulty. Coughing may develop if airways are compressed or infiltrated. These signs may develop gradually or present more acutely depending on the pattern and pace of involvement.

Click to read about the biological mechanisms

How this is usually investigated

Investigating suspected lymphoma in dogs typically involves confirming the diagnosis, characterising the subtype and immunophenotype, and assessing the extent of disease spread (staging). This information collectively informs the understanding of the likely disease behaviour and helps frame discussions about management options. The investigation process generally progresses from minimally invasive sampling to more comprehensive assessment based on the clinical context.

Fine needle aspirate cytology

Purpose: A thin needle is inserted into an enlarged lymph node (or other affected tissue) to extract a small sample of cells for microscopic examination. Cytology can often rapidly confirm a population of abnormal lymphocytes consistent with lymphoma, providing a presumptive diagnosis without requiring a more invasive biopsy. This technique is minimally invasive, typically well-tolerated without sedation, and can yield results relatively quickly.
Considerations: Cytology provides information about cell morphology but may not always differentiate lymphoma from reactive lymph node enlargement or other round cell tumours with certainty. It may not provide sufficient information for definitive immunophenotyping or histological grading, which can influence management decisions. In ambiguous cases, additional sampling or tissue biopsy may be needed.

Immunophenotyping (flow cytometry or immunohistochemistry)

Purpose: Determining whether the lymphoma cells are of B-cell or T-cell origin provides important prognostic information, as B-cell lymphomas generally respond more favourably to standard chemotherapy protocols and tend to carry longer remission durations than T-cell lymphomas. Flow cytometry can be performed on aspirate samples, whilst immunohistochemistry requires tissue sections from a biopsy. Some laboratories also assess clonality through PCR-based assays (PARR testing), which can help confirm the diagnosis in ambiguous cases.
Considerations: The prognostic value of immunophenotyping, whilst significant at a population level, does not predict the individual outcome for any specific dog with certainty. Access to flow cytometry may vary by laboratory. The distinction between B-cell and T-cell lymphoma influences prognostic discussions but does not typically change the fundamental treatment approach, though it may affect the choice of rescue protocol if relapse occurs.

Histopathological biopsy

Purpose: Surgical excision of an entire lymph node or an incisional biopsy provides tissue architecture that allows histological grading and classification of the lymphoma subtype. This information can complement cytological findings and immunophenotyping, providing a more complete characterisation of the disease. Histopathology is particularly valuable when cytology is inconclusive or when distinguishing between lymphoma and other lymph node pathologies.
Considerations: Biopsy is more invasive than fine needle aspirate and typically requires sedation or general anaesthesia. The additional information provided by histopathology may or may not change the management approach in straightforward cases where cytology has already provided a confident diagnosis. In some situations, the practical benefits of biopsy must be weighed against the delay in initiating treatment and the procedural considerations.

Staging investigations

Purpose: Clinical staging assesses the extent of disease spread throughout the body and typically includes blood work (complete blood count, biochemistry panel including calcium), urinalysis, thoracic radiographs, abdominal ultrasound, and sometimes bone marrow aspirate. This comprehensive assessment identifies which organs and systems are involved, reveals complications such as hypercalcaemia, and provides a baseline against which treatment response can be measured. The World Health Organization staging system for canine lymphoma classifies the disease from Stage I (single lymph node) to Stage V (bone marrow or blood involvement).
Considerations: Complete staging involves multiple procedures and associated costs, and the extent of staging pursued may be tailored to the individual situation. Some staging findings, such as bone marrow involvement or the presence of hypercalcaemia, carry prognostic significance. The substage designation — 'a' for clinically well dogs versus 'b' for dogs showing signs of illness — is itself an important prognostic indicator, with substage 'a' dogs generally having better outcomes.

Blood calcium and organ function assessment

Purpose: Serum calcium measurement is particularly important because paraneoplastic hypercalcaemia occurs in a significant subset of dogs with lymphoma, especially those with T-cell immunophenotype, and can cause kidney damage if sustained. Assessment of liver and kidney function through biochemistry panels helps identify organ involvement and establishes whether any concurrent organ compromise needs to be addressed before or alongside treatment. Complete blood count evaluation reveals whether the bone marrow is affected (leukaemic phase) and identifies any pre-existing cytopenias that might influence treatment safety.
Considerations: Ionised calcium is a more accurate measure of clinically relevant hypercalcaemia than total calcium, but may not be available at all laboratories. Pre-existing organ dysfunction identified during staging can influence both the choice and dosing of chemotherapy agents. Some biochemical abnormalities may resolve with treatment of the lymphoma itself.

Options & trade-offs

Management of lymphoma in dogs encompasses a spectrum of approaches, from multi-agent chemotherapy protocols aimed at inducing remission to palliative strategies focused on maintaining comfort and quality of life. The choice of approach is influenced by the lymphoma subtype and immunophenotype, the stage and extent of disease, the individual dog's overall health, and the owner's goals and circumstances. It is important to note that treatment of lymphoma in dogs is generally aimed at controlling the disease and maintaining quality of life rather than achieving cure, as most dogs will eventually relapse.

Multi-agent chemotherapy protocols

Combination chemotherapy using multiple drugs administered in a rotating sequence (such as CHOP-based protocols using cyclophosphamide, doxorubicin, vincristine, and prednisolone) represents the approach most commonly associated with achieving complete remission and the longest survival times in canine lymphoma. These protocols typically involve weekly or bi-weekly veterinary visits over an induction period of several months, followed by a maintenance phase or treatment cessation. The majority of dogs with B-cell multicentric lymphoma achieve complete remission with multi-agent protocols, meaning that all detectable evidence of disease temporarily resolves.

Trade-offs: Multi-agent protocols involve the most intensive treatment schedule, with frequent visits and multiple different medications, each carrying its own side effect profile. Whilst most dogs tolerate chemotherapy well, gastrointestinal effects, bone marrow suppression, and occasional more significant complications can occur. The financial commitment over the full treatment course is typically substantial. Despite achieving remission, most dogs will eventually relapse, and second remissions, whilst often achievable, tend to be shorter than the first.

Single-agent chemotherapy

Treatment with a single chemotherapy drug, such as doxorubicin alone, offers a less intensive alternative to multi-agent protocols whilst still aiming to achieve remission. Single-agent protocols typically involve less frequent veterinary visits (often every three weeks) and a simpler treatment schedule. Remission rates and durations with single-agent treatment are generally somewhat lower than with multi-agent protocols, though meaningful responses are still commonly achieved.

Trade-offs: The trade-off between simplicity and efficacy is the central consideration with single-agent approaches. Fewer visits and a simpler protocol may better suit certain owners' circumstances, but the expected duration of remission is typically shorter than with multi-agent treatment. Some single agents, particularly doxorubicin, carry specific toxicity risks (such as cumulative cardiac effects) that limit the total number of doses that can be administered.

Prednisolone (corticosteroid) alone

Corticosteroid therapy with prednisolone can produce temporary reduction in lymph node size and improvement in clinical signs in many dogs with lymphoma, as corticosteroids have direct cytotoxic effects on lymphoid cells. This approach is sometimes chosen when owners wish to pursue some form of treatment without the complexity of chemotherapy, or as an initial measure whilst other options are being considered. The response is typically rapid, with visible lymph node reduction often occurring within days.

Trade-offs: Remission achieved with prednisolone alone is generally short-lived, typically lasting only a few weeks to a couple of months before the disease progresses. Of particular concern, prior prednisolone exposure may reduce the likelihood and duration of remission if multi-agent chemotherapy is subsequently pursued, a phenomenon attributed to the selection of drug-resistant cell populations. The side effects of prednisolone, including increased thirst, urination, appetite, and potential muscle wasting, can affect quality of life. This approach is therefore sometimes viewed as a palliative measure rather than a treatment aimed at sustained remission.

Rescue and second-line protocols

When lymphoma relapses after initial treatment, alternative drug combinations (rescue protocols) may be employed to attempt a second or subsequent remission. These protocols use drugs that the cancer cells have not yet been exposed to or that work through different mechanisms, aiming to overcome the resistance that developed during initial treatment. Various rescue protocols have been described, using agents such as lomustine, cytosine arabinoside, mitoxantrone, L-asparaginase, or combinations thereof.

Trade-offs: Second and subsequent remissions are generally achievable but tend to be shorter in duration than the initial remission, reflecting the progressive development of drug resistance within the cancer cell population. The cumulative effects of sequential chemotherapy protocols on the patient's bone marrow reserves, organ function, and overall resilience require careful consideration. The decision to pursue rescue treatment involves reassessing the balance between potential benefit and the burden of additional treatment for both the dog and the owner.

Palliative and comfort-focused care

For owners who prefer not to pursue chemotherapy, or when treatment options have been exhausted, palliative care focuses on maintaining the dog's comfort and quality of life for as long as possible. This may include prednisolone for temporary symptom relief, pain management, nutritional support, anti-nausea medications, and attention to the dog's daily comfort and enjoyment. The emphasis shifts from disease control to ensuring that the time remaining is spent comfortably and meaningfully.

Trade-offs: Palliative care alone does not attempt to achieve remission or substantially alter the disease trajectory, meaning the expected time frame is typically shorter than with chemotherapy-based approaches. However, the absence of chemotherapy-related side effects and the reduced treatment burden can contribute positively to quality of life during the remaining time. The decision to pursue palliative care is entirely valid and reflects a focus on comfort over treatment intensity.

Common misconceptions

Misconception:

"Chemotherapy in dogs causes the same severe side effects seen in human cancer treatment"

Reality:

Chemotherapy protocols for dogs are designed with quality of life as a primary consideration, and the doses used are generally lower than those in human oncology, where the goal of cure may justify more aggressive treatment. Whilst side effects can occur — including gastrointestinal upset, temporary bone marrow suppression, and occasional more significant complications — the majority of dogs tolerate chemotherapy well and maintain good quality of life throughout treatment. Hair loss is uncommon in most breeds, though dogs with continuously growing coats (such as Poodles and Old English Sheepdogs) may experience noticeable hair thinning.

Misconception:

"If a dog has lymphoma, treatment is not worthwhile because it cannot be cured"

Reality:

Whilst it is true that lymphoma in dogs is generally considered a manageable rather than curable disease, many dogs achieve sustained remissions during which they are clinically indistinguishable from healthy dogs. The quality of life during remission is often excellent, with dogs returning to normal activities, appetite, and energy levels. The decision about whether to pursue treatment is deeply personal and depends on many factors, but the potential for meaningful periods of good-quality life during remission is an important consideration.

Misconception:

"Enlarged lymph nodes always mean lymphoma"

Reality:

Lymph node enlargement (lymphadenopathy) can result from a wide range of causes including infections, immune-mediated conditions, reactive hyperplasia in response to local inflammation or vaccination, and other types of cancer besides lymphoma. The pattern of enlargement, the speed of onset, the clinical context, and cytological or histological examination of the lymph node tissue are all needed to distinguish lymphoma from other causes. Not all lymph node swellings represent cancer, and investigation is needed to determine the underlying cause.

Understanding lymphoma as a systemic disease with variable behaviour depending on its subtype and individual factors can help frame the experience of living with an affected dog. Many dogs with lymphoma maintain an excellent quality of life during periods of remission, and the goal of management is typically to maximise the duration and quality of that time. The emotional dimension of navigating a cancer diagnosis in a companion animal is significant, and owners' decisions about management are deeply personal, influenced by their individual circumstances, values, and relationship with their dog. The field of veterinary oncology continues to evolve, with ongoing research into new therapeutic targets, immunotherapies, and personalised medicine approaches that may expand the management landscape in the future.

Last reviewed: 24 April 2026 · Dr Alastair Greenway MRCVS